Maven Clinic
Maven Clinic runs virtual clinical care for fertility, maternity and family health as an employer benefit.
On the record
Checkpoint: Next major enterprise renewal cycle and possible Series G or IPO signal
The call
Maven holds a regulated clinical position that AI cannot easily route around, but the real fight is against Progyny and Carrot for the same employer dollars, with funding and account renewals as the next scorecards.
Maven Clinic connects patients to licensed doctors for fertility treatment and related health care, mostly through employer plans. It is hard to replace because it needs state licenses, accreditation from a national board, and long-term data showing it works, plus employer contracts that lock in for years. A competitor called Progyny, which is already public and larger, is directly fighting Maven for the same employers like Amazon, and artificial intelligence cannot do what Maven does because it requires real doctors in multiple states and legal responsibility. The one thing that could change everything is whether Maven keeps its biggest employer customers when contracts come up for renewal, or loses them to Progyny or similar rivals.
Why
01
AI pressure: None apparent. Licensed multi-state care and clinical liability block chatbot replacement; Maven uses AI (Maven Intelligence) to route members, not replace clinicians. Could AI do the core job? Unlikely.
02
Bigger players: Progyny. Progyny is public, scaled, and actively competing for the same enterprise fertility contracts, including past runs at Amazon. Could a giant copy it? Probably.
03
What protects it. Employer contracts, NCQA accreditation, and a licensed multi-state provider network are hard for a model or a generalist to copy fast.
What would change this call
Amazon renews or switches its fertility benefit away from Maven at next contract cycle. Would show whether Maven's marquee account is stable or being won back by Progyny.
Maven announces a new funding round or IPO filing within the next 12 months. Would show whether investors still back growth after a 21-month funding gap.
Maven's D2C consumer platform reports retention or revenue figures. Would show whether the March-May 2026 consumer pivot is gaining real traction.
Maven announces a new funding round or IPO filing within the next 12 months. Would show whether investors still back growth after a 21-month funding gap.
Maven's D2C consumer platform reports retention or revenue figures. Would show whether the March-May 2026 consumer pivot is gaining real traction.
Key numbers
- 28M covered lives, up from 17M in 2024
- ~$268M ARR, +26% YoY
- 1,176 employees, +12.6% YoY
Named risks
- 21 months with no new funding round since October 2024 Series F raises burn and valuation-momentum questions.
- 10% workforce layoff in November 2024 shortly after a large raise signals cost discipline issues.
- Unproven direct-to-consumer pivot launched March 2026 competes with established consumer telehealth and GLP-1 platforms.
- Conflicting third-party revenue estimates ($268M vs $146.8M) show limited financial transparency as a private company.
- Independent review gives Maven's patient-facing terms of service a Grade F for broad liability waivers.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Progyny | contesting | Maven won Amazon account from Progyny Sept 2024, but Progyny still has larger overall revenue as of Dec 2024 |
| Carrot Fertility | contesting | Carrot claims 4M+ lives across 1,000+ clients as of 2026, competing for same employer RFPs |
| Kindbody | gaining on | Analyst estimate says Kindbody's owned-clinic model undercuts Maven on price, per Jan 2026 industry analysis |
| Teladoc/MDLIVE (Evernorth) | contesting | Broad telehealth incumbent adjacent to Maven's virtual care category, per CBInsights July 2026 listing |
Questions people ask
- Is Maven Clinic profitable in 2026?
- No profitability figure is disclosed. Maven reported roughly $268M ARR for 2024, up about 26% YoY, but the company laid off about 60 employees (10% of staff) in November 2024 right after closing its $125M Series F, suggesting it was still managing burn, not banking profit.
- Could AI replace Maven Clinic's services?
- Unlikely soon. Maven delivers regulated, licensed clinical care through 1,000+ vetted providers and holds NCQA Health Equity Accreditation (December 2024). Its March 17, 2026 Maven Intelligence launch uses AI to orchestrate care, not substitute the human provider relationship required for liability and licensing.
- Who is Maven Clinic's biggest competitor?
- Progyny (NASDAQ: PGNY) is the closest rival, with about 6.47 million covered lives across 473 employer clients as of December 2024 and generally larger revenue than Maven. Maven won Amazon's fertility benefit contract from Progyny in September 2024, showing the rivalry is active on both sides.
- Who owns Maven Clinic?
- Maven Clinic is privately owned and venture-backed, founded in 2014 by Kate Ryder. Its most recent funding was a $125M Series F led by StepStone Group in October 2024, valuing the company at $1.7B post-money, with no new round reported through July 2026.
- Has Maven Clinic had layoffs?
- Yes. Maven laid off approximately 60 employees, about 10% of its workforce, in early November 2024, just weeks after closing its $125M Series F funding round at a $1.7B valuation.
- What is Maven Clinic's current valuation?
- Maven Clinic was valued at $1.7 billion post-money after its $125M Series F round closed on October 9, 2024, led by StepStone Group, bringing total funding raised to over $425 to 437 million.
Timeline
- 2026-07-15Maven files public comment supporting proposed federal excepted fertility benefits rule
- 2026-05-20Maven expands direct-to-consumer platform nationwide with GLP-1 and hormonal care
- 2026-03-17Launches Maven Intelligence AI orchestration layer at NVIDIA GTC conference
- 2026-03-11Launches direct-to-consumer subscription platform, first outside employer benefits
- 2024-12Becomes first women's health company to earn NCQA Health Equity Accreditation
- 2024-11-01Lays off about 60 employees, roughly 10% of workforce
- 2024-10-09Closes $125M Series F at $1.7B post-money valuation, led by StepStone Group
- 2024-09Amazon switches primary fertility benefit provider from Progyny to Maven
- 2023-03Acquires Naytal, a UK virtual women's health platform
- 2022-06Closes $90M Series E at $1.35B valuation, led by General Catalyst
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Maven Clinic (2026-07-18)
- A ten-year roadmap in women's and family health (2026-07-11)
- Maven Clinic revenue, valuation & funding
- $268M ARR, $1.7B Valuation (2025-11-27)
- Unicorn Maven raises $90M as focus on women's healthcare sharpens
- Maven Clinic Introduces Maven Intelligence (2026-03-17)
- Maven Clinic, Contrary Research Company Profile & Resources
- Maven Clinic Number of Employees 2026 (2026-06-29)
- Maven Clinic - Headcount, Funding & Open Jobs (2026-07-08)
- Maven Clinic cuts 10% of workforce weeks after raising $125M (2024-11-01)
- Working at Maven Clinic (2026-06-30)
- Maven Is Opening Its Doors to Women Nationwide (2026-03-11)